Inhibrx Biosciences (INBX) Liabilities and Shareholders Equity (2023 - 2025)
Historic Liabilities and Shareholders Equity for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $177.5 million.
- Inhibrx Biosciences' Liabilities and Shareholders Equity fell 2026.0% to $177.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $813.0 million, marking a year-over-year increase of 305.78%. This contributed to the annual value of $180.8 million for FY2024, which is 4128.9% down from last year.
- Per Inhibrx Biosciences' latest filing, its Liabilities and Shareholders Equity stood at $177.5 million for Q3 2025, which was down 2026.0% from $212.1 million recorded in Q2 2025.
- Over the past 5 years, Inhibrx Biosciences' Liabilities and Shareholders Equity peaked at $307.9 million during Q4 2023, and registered a low of $177.5 million during Q3 2025.
- Moreover, its 3-year median value for Liabilities and Shareholders Equity was $222.6 million (2024), whereas its average is $228.8 million.
- As far as peak fluctuations go, Inhibrx Biosciences' Liabilities and Shareholders Equity tumbled by 4128.9% in 2024, and later crashed by 1791.67% in 2025.
- Inhibrx Biosciences' Liabilities and Shareholders Equity (Quarter) stood at $307.9 million in 2023, then tumbled by 41.29% to $180.8 million in 2024, then fell by 1.82% to $177.5 million in 2025.
- Its last three reported values are $177.5 million in Q3 2025, $212.1 million for Q2 2025, and $242.6 million during Q1 2025.